This inventor holds 1 USPTO granted patent and 9 published patent applications. Active years: 2026.
Years Active: 2026
Title: Michael M Yamano: Innovator in Macrocyclic Compounds
Introduction
Michael M Yamano is a notable inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific mutations in the KRAS gene, which are associated with various cancers. His innovative work has the potential to impact cancer treatment significantly.
Latest Patents
Yamano holds a patent for "Macrocyclic compounds and methods of use." This patent provides compounds that are useful for the inhibition of KRAS mutations, including G12D, G12V, G12A, G12S, G13D, Q61H, Q61L, and G12C. The compounds are described by a general Formula I′, with specific variables defined within the patent. Additionally, the disclosure includes pharmaceutical compositions that comprise these compounds, highlighting their potential uses in cancer treatment.
Career Highlights
Throughout his career, Michael M Yamano has focused on the intersection of chemistry and medicine. His work has led to advancements in the understanding and treatment of cancer, showcasing his dedication to improving patient outcomes through innovative research.
Collaborations
Yamano has collaborated with notable colleagues, including Liping Pettus and Brian Alan Lanman. These partnerships have contributed to the development and refinement of his patented compounds, enhancing the overall impact of his research.
Conclusion
Michael M Yamano's contributions to the field of pharmaceutical chemistry, particularly through his patent on macrocyclic compounds, demonstrate his commitment to advancing cancer treatment. His innovative work continues to pave the way for new therapeutic options in the fight against cancer.